Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients.
Роберто Пили(Jacobs Institute), Noah M. Hahn(Johns Hopkins University), Heather Burney(Indiana University – Purdue University Indianapolis), Sara I Edwards(Indiana University Health), David I. Quinn(USC Norris Comprehensive Cancer Center), Costantine Albany(Indiana University Health), Justin A. Budka(Gilead Sciences (United Kingdom)), Nabil Adra(Indiana University Health), James Fletcher(Hôpital de Sion), Hao Liu(Rutgers, The State University of New Jersey), Mark Green(University of Liverpool), Theodore F. Logan(Indiana University Health), Andrew Greenspan(Indiana Cancer Consortium), Mark Tann(Indiana University – Purdue University Indianapolis), Nur P. Damayanti(University of Indianapolis)
Cited by 21
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2017|1.3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k